buclizine hydrochloride + codeine + paracetamol: clinical use

Prescribing considerations

• Confirm medically diagnosed migraine and that the licensed indication is met.
• Review all sources of paracetamol, opioids, sedatives and antimuscarinic burden.
• Assess respiratory reserve, renal and hepatic function, biliary or pancreatic disease, constipation, urinary-retention risk and susceptibility to angle-closure glaucoma.
• Assess substance-use, tobacco-use and relevant mental-health history.
• Discuss treatment goals, stopping strategy, dependence, medication-overuse headache and opioid-toxicity signs.

Contraindications and cautions

• Hypersensitivity to an active ingredient or excipient.
• Age under 12 years.
• Breastfeeding.
• Known CYP2D6 ultra-rapid metaboliser status.
• Acute respiratory depression.
• Head injury or raised intracranial pressure.
• Obstructive bowel disorder or risk of paralytic ileus.
• Use after tonsillectomy or adenoidectomy for obstructive sleep apnoea in anyone under 18 years.

Monitoring

• Analgesic response and continuing clinical need.
• Sedation, cognition and respiratory status.
• Constipation and other antimuscarinic effects.
• Escalating use, loss of effect, drug-seeking behaviour, withdrawal or opioid-induced hyperalgesia.
• Headache frequency and possible medication-overuse headache.
• Liver-risk factors and duplicate paracetamol exposure.

Clinical pharmacology

Codeine is a weak centrally acting opioid prodrug converted by CYP2D6 to morphine. Paracetamol provides central analgesic activity, while buclizine is a sedating H1-receptor antagonist with antimuscarinic and antiemetic properties.

Formulation and product differences

• The selected formulation is a pink, capsule-shaped, film-coated tablet marked “MGE” on one face and contains all three active ingredients.
• The product is marketed in pharmacy and prescription-only pack categories; legal status differs by pack size.